News | Cardiovascular Business | July 19, 2022

CMS Releases 2023 Medicare Physician Fee Schedule Proposed Rule

 AUC mandate penalty phase will not begin Jan. 1, 2023 

On July 7, the Centers for Medicare & Medicaid Services (CMS) released the 2023 Medicare Physician Fee Schedule (PFS) proposed rule

Getty Images


July 19, 2022 — On July 7, the Centers for Medicare & Medicaid Services (CMS) released the 2023 Medicare Physician Fee Schedule (PFS) proposed rule. In the days ahead the American Society of Nuclear Cardiology’s (ASNC) advocacy team will analyze the proposed rule and report to you on specifics that may impact your practice as well as any actions ASNC will take. CMS also posted a notice about the AUC Mandate.  

The society shared the following top-line analysis from these documents:  

Conversion Factor 

CMS’s proposed conversion factor for CY2023 is $33.08, which takes into account the statutorily required update to the conversion factor for CY2023 of 0 percent, the expiration of the 3 percent increase in PFS payments for CY2022 provided by Congress and the statutorily required budget neutrality adjustment to account for changes in relative value units. This conversion factor represents a decrease of $1.53 from the CY2022 PFS conversion factor of $34.61. 

If these conversion factor reductions are finalized, there will be payment cuts affecting services across the entire physician fee schedule. 

Stay tuned for payment charts compiling the CY2023 proposed Medicare PFS reimbursement rates for nuclear cardiology services. ASNC offers these valuable charts as a membership benefit. The advocacy team also will provide an analysis of the potential impact on nuclear cardiology reimbursement. 

Medicare Appropriate Use Criteria Program 

While the proposed rule is silent on the Medicare Appropriate Use Criteria (AUC) Program for advanced diagnostic imaging, CMS has provided notice that the payment penalty phase of the AUC Mandate will not begin January 1, 2023, even if the public health emergency for COVID-19 ends in 2022. 

CMS further states that, until further notice, the educational and operations testing period will continue and that CMS is “unable to forecast when the payment penalty phase will begin.”
CMS had previously finalized that the penalty phase of the AUC program would begin on January 1, 2023, or the first January 1 following the end of the COVID-19 public health emergency. 

For more information: www.asnc.org 


Related Content

News | Cardiovascular Business

July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing ...

Home July 29, 2024
Home
News | Cardiovascular Business

July 18, 2024 — Circle Cardiovascular Imaging, a developer of artificial intelligence (AI)-driven cardiovascular imaging ...

Home July 18, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Guidehealth, an artificial intelligence (AI)-enabled healthcare services company, has announced a ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Edwards Lifesciences announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 11, 2024 — Medical device company R3 Vascular Inc., developer of novel, best-in-class bioresorbable scaffolds for ...

Home July 11, 2024
Home
News | Cardiovascular Business

July 9, 2024 — Disparities in cardiovascular disease outcomes between urban and rural areas continue to widen, yet ...

Home July 09, 2024
Home
Feature | Cardiovascular Business

The DAIC team wishes you a safe and happy 4th of July!

Home July 04, 2024
Home
News | Cardiovascular Business

July 3, 2024 — Over the past decade, 342 cardiology clinics have been acquired by private equity firms, with over 94% of ...

Home July 03, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

From FDA approvals to new clinical trials, here is a look at DAIC's top-read content during the month of June: 1 ...

Home July 02, 2024
Home
News | Cardiovascular Business

July 1, 2024 — CVRx, Inc., a commercial-stage medical device company, announced three additions to its senior leadership ...

Home July 01, 2024
Home
Subscribe Now